Sign in

Christopher Graber

@idsensei.bsky.social
1.8K followers 121 following 105 posts

ID doc, steward, dad, fellowship program director

PostsRepliesMedia
Reposted by Christopher Graber
Paul Sax @paulsaxmd.bsky.social · 03/04/2026
One-month treatment for latent tuberculosis. Why aren't we using it? (Hint: We should.) voices.nejm.org/doi/full/10....
voices.nejm.org
One-Month Treatment for Latent Tuberculosis
Why aren’t we using it?
32313
Reposted by Christopher Graber
IDSA @idsainfo.bsky.social · 30/03/2026
On IDSA’s & HIVMA’s Science Speaks blog: A study in CID looked at clinical features and predictors of mortality for Legionella pneumonia across a large integrated health system. Read IDSA’s Journal Club review by Christopher J. Graber, MD, MPH, FIDSA: bit.ly/3NOpG4M
bit.ly
Troubled waters: Legionella pneumonia in the modern era
A study in CID looked at clinical features and predictors of mortality for Legionella pneumonia. Read IDSA's Journal Club review by Christopher J. Graber, MD, MPH, FIDSA.
002
Reposted by Christopher Graber
Joseph Marcus @josephmarcusid.medsky.social · 28/03/2026
Should ID provide primary care to patients with HIV? Point and counter point in @cidjournal.bsky.social Work with primary care for PLWH: doi.org/10.1093/cid/... Work as primary care for PLWH: doi.org/10.1093/cid/... #IDSky
doi.org
Providing the Best Infectious Diseases and Primary Care to Our Patients With HIV: Time for Delivery Models to Evolve
Advances in care for patients with human immunodeficiency virus have simplified the management of infectious disease–related conditions, yet primary care h
094
Christopher Graber @idsensei.bsky.social · 27/03/2026
Would love to spark a discussion with our recent point-counterpoint in CID on the future of ID-HIV primary care. My colleagues and I argue that we AND our patients are better off leaving the intricacies of primary care to those who do it more than we do. academic.oup.com/cid/advance-...
academic.oup.com
Providing the Best Infectious Diseases and Primary Care to Our Patients With HIV: Time for Delivery Models to Evolve
Advances in care for patients with human immunodeficiency virus have simplified the management of infectious disease–related conditions, yet primary care h
161
Christopher Graber @idsensei.bsky.social · 12/03/2026
what I like about Roon so far: 1. More back-and-forth discussion 2. Ability to follow certain topics in “spaces” (e.g., AI in medicine, health policy, med ed, medical reasoning) 3. You can’t tell how many followers you have (less clout-chasing and virtue signaling) 4. No bots or trolls
020
Christopher Graber @idsensei.bsky.social · 12/03/2026
Remember the glory days of #IDTwitter? Want to have discussions with your colleagues without sifting through the slop of X and the echo chambers of Bluesky? Come join what we are building over at Roon!
210
Christopher Graber @idsensei.bsky.social · 20/02/2026
Bruin. Doin’ us proud.
000
Christopher Graber @idsensei.bsky.social · 19/02/2026
Are you an ID pharmacist currently in the VA system who wants to live in an awesome city and work with awesome people? Look no further. www.usajobs.gov/job/858066800
usajobs.gov
USAJOBS connects job seekers with federal jobs across the United States and around the world as the official employment site for the federal government
The Clinical Pharmacist Specialist for Infectious Diseases must be a licensed pharmacist, have expert knowledge of infectious disease/antimicrobial medication therapy and management, and have an exper...
000
Christopher Graber @idsensei.bsky.social · 18/02/2026
My latest for IDSA Journal Club: a review of a recent CID paper that finds similar outcomes in CAP patients with pos viral testing when treated with 0-2d vs 5-7d abx, adding fuel to recent IDSA-ATS controversy. www.idsociety.org/science-spea...
idsociety.org
Antibiotics in community-acquired pneumonia when respiratory viruses are detected: Adding more fuel to the fire?
A study in CID examined associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays.
010
Christopher Graber @idsensei.bsky.social · 13/02/2026
just referred to a smoldering leukocytosis as “low-key” on rounds today…not sure if I’m chopped, cringe, or goated
220
Christopher Graber @idsensei.bsky.social · 09/01/2026
I did not have @mmpharmd.bsky.social making a 6-7 reference in a CID article on my bingo card of things that were going to make my day today but here we are academic.oup.com/cid/advance-...
academic.oup.com
Validate User
141
Christopher Graber @idsensei.bsky.social · 17/12/2025
did ABIM really just send me my LKA Wrapped?
000
Christopher Graber @idsensei.bsky.social · 16/12/2025
we’re talkin’ CloCeBa at @idsainfo.bsky.social Journal Club this month! Do we need to think about adding blaZ type to rapid diagnostic panels for MSSA bacteremia? www.idsociety.org/science-spea...
idsociety.org
Anti-staphylococcal penicillins versus cefazolin for methicillin-susceptible S. aureus bacteremia: Is there a role for determining blaZ type?
A study in The Lancet addressed cloxacillin versus cefazolin for methicillin-susceptible S. aureus bacteremia. Read IDSA’s Journal Club review by Christopher J. Graber.
011
Christopher Graber @idsensei.bsky.social · 01/12/2025
The 6 “coms” of why we are losing the battle over public health: complacency, commitment, commercialism, complexity, communication, and comportment www.nejm.org/doi/full/10....
nejm.org
Restoring Confidence in Public Health | NEJM
A confluence of interrelated factors has put past progress in public health at serious risk in the United States. How did we get here, and what can public health professionals do about it?
020
Reposted by Christopher Graber
UW Infectious Disease Fellowship Program @uwidfellowship.bsky.social · 07/11/2025
With UW’s Dr Paul Pottinger and others, new discussion re: fostering ID advocacy in ID fellowship. They note: Policies with a negative impact on ID clinical care, public health, & research underscore the importance of mobilizing the field of ID to advocacy academic.oup.com/ofid/advance... #IDSky
academic.oup.com
Amplifying Our Voices: Fostering Advocacy in Infectious Diseases Fellowship
This white paper, devised from the Infectious Diseases Society of America's National Training Program Director annual meeting, outlines practical strategie
043
Christopher Graber @idsensei.bsky.social · 24/10/2025
beginning to realize the stages of @idweek.bsky.social attendance according to career stage: 1. The Learner: the student/resident/fellow that goes to learn and absorb.
120
Reposted by Christopher Graber
Joanna Schaenman, MD, PhD @jschaenmanmd.bsky.social · 24/10/2025
Feeling inspired seeing so many enthusiastic trainees at #IDWeek2025! We have a 2026-27 opening for our 1-year Transplant ID Advanced Training Program at #UCLA, pls reach out with any questions #IDfellow #TxID @idweek.bsky.social #IDSky @ucla-id-fellowship.bsky.social recruit.apo.ucla.edu/JPF10380
recruit.apo.ucla.edu
Transplant Infectious Diseases Career Development Position 2026-2027
University of California, Los Angeles is hiring. Apply now!
187
Christopher Graber @idsensei.bsky.social · 23/10/2025
Well done to all the teams! Time for everyone to start making plans for BugBowl 2026 in DC!
010
Christopher Graber @idsensei.bsky.social · 22/10/2025
Get psyched! Come for the ATL-themed puns, stay for the knowledge!
021
Reposted by Christopher Graber
IDSA @idsainfo.bsky.social · 17/10/2025
On IDSA’s & HIVMA’s Science Speaks blog: Christopher J. Graber, MD, MPH, FIDSA, explores dalbavancin versus standard therapy for completion of treatment of complicated S. aureus bacteremia. bit.ly/4ncqnAt
idsociety.org
DOT-ting i's and crossing t's: More evidence for using long-acting glycopeptides to finish therapy of complicated S. aureus bacteremia
A JAMA study looked at dalbavancin versus standard therapy for completion of treatment of complicated S. aureus bacteremia. Read IDSA's Journal Club review.
062
Christopher Graber @idsensei.bsky.social · 29/09/2025
Looking to do some stewardship and/or hospital epi? Join me, @wbranchelliman.bsky.social, and our crew at VA Greater Los Angeles!
151
Christopher Graber @idsensei.bsky.social · 24/09/2025
best admin assistant (and pre-interview Zoom DJ) ever!
030
Reposted by Christopher Graber
Tara Vijayan @nottheogdrv.bsky.social · 04/09/2025
Colleagues- in case this was missed during summer vacation, please share. I just went to the Bowl again last week and saw Yo-Yo Ma and Angelique Kidjo. The Bowl is not the only reason to be in LA....but it is pretty spectacular. Also my ASP team is just the bee's knees.
021
Christopher Graber @idsensei.bsky.social · 12/08/2025
the marker of a good journal club is that the fellows have already left for clinic and the attendings are still arguing
150
Christopher Graber @idsensei.bsky.social · 09/08/2025
I demand a randomized controlled trial of hiring people who resign back to their prior jobs. The public deserves nothing less.
020
Christopher Graber @idsensei.bsky.social · 04/08/2025
Moderate immunocompromise (even if overly broadly defined) should not buy you vanc + antipseudomonal for CAP: my latest @idsainfo.bsky.social Journal Club review: www.idsociety.org/science-spea...
idsociety.org
Broad-spectrum antibiotics for moderately immunocompromised patients with CAP: An overdone practice
A study in CID examined broad-spectrum antibiotics in moderately immunocompromised patients with community-acquired pneumonia
0125
Christopher Graber @idsensei.bsky.social · 01/08/2025
my fellow just put up a slide in case conference with the “distracted boyfriend” meme for linezolid overtaking clindamycin as the “toxin” drug of choice and never have I been more proud as a program director
020
Christopher Graber @idsensei.bsky.social · 31/07/2025
let’s goooooooooooooo
010
Christopher Graber @idsensei.bsky.social · 22/07/2025
we’ve all been there, right?
060
Christopher Graber @idsensei.bsky.social · 18/07/2025
most men aren’t complicated, it turns out (at least as it pertains to UTI)
271
Christopher Graber @idsensei.bsky.social · 10/07/2025
you’re damn right I’m giving feedback on every internal medicine LKA question I miss as being a bad question
060
Christopher Graber @idsensei.bsky.social · 09/07/2025
good reminder for all the new trainees: antibiotics don’t fix structural abnormalities
010
Christopher Graber @idsensei.bsky.social · 06/07/2025
ID is about so much more than picking the correct antibiotics
031
Reposted by Christopher Graber
IDSA @idsainfo.bsky.social · 02/07/2025
On IDSA’s & HIVMA’s Science Speaks blog: A study in OFID examined the impact of antibiotic duration on gut microbiome composition and antimicrobial resistance. Read IDSA’s Journal Club review by Christopher J. Graber, MD, MPH, FIDSA. buff.ly/CDwwOlf
idsociety.org
Shorter may be better, but how (and how much better)?
A study in OFID examined the impact of antibiotic duration on gut microbiome composition and antimicrobial resistance.
141
Christopher Graber @idsensei.bsky.social · 27/06/2025
IDSA Journal Club is back, baby! My latest on the perhaps questionable effect of shortening antimicrobial courses of therapy on the gut microbiome: www.idsociety.org/science-spea...
idsociety.org
Shorter may be better, but how (and how much better)?
A study in OFID examined the impact of antibiotic duration on gut microbiome composition and antimicrobial resistance.
031
Reposted by Christopher Graber
IDSA @idsainfo.bsky.social · 05/05/2025
Deadline approaching! Submit your team of ID trivia powerhouses to compete in IDBugBowl, a Jeopardy-style competition held at #IDWeek2025: buff.ly/JUFUcel IDWeek will pay FULL conference registration for student, resident & fellow team participants. Apply by 5/16.
001
Reposted by Christopher Graber
UCLA Multicampus Fellowship in Infectious Diseases @ucla-id-fellowship.bsky.social · 28/04/2025
It takes a village! So many past/present/future fellows on this paper examining Karius utilization: most clinical impact seen with cx neg IE and concern for fastidious/zoonotic/vectorborne pathogens www.cambridge.org/core/journal...
cambridge.org
Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay | Infection Control & Hospital Epidemiology | Cambridge Core
Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay - Volume 46 Issue 5
031
Christopher Graber @idsensei.bsky.social · 26/04/2025
get those applications in!
021
Christopher Graber @idsensei.bsky.social · 24/04/2025
so I am starting to bring up lessons I have learned from Dan Campbell (Detroit Lions coach) in talks on leadership in antimicrobial stewardship. Question from a colleague: What is the ASP equivalent of going for it on 4th down?
220
Christopher Graber @idsensei.bsky.social · 22/04/2025
was discussing the vagaries of diagnosing osteomyelitis in conference today as to whether osteo was bona fide or not and someone said “don’t you mean bony fide” so that’s what I’m calling it now
040
Reposted by Christopher Graber
Anne Lamott @annelamott.bsky.social · 18/04/2025
Here is the gift link to a new piece I wrote for this mornings Washington post. You don't need to be a subscriber: wapo.st/42EsQeM
wapo.st
Opinion | Loving the nickel life
Could it be true that I was born for a time like this?
56912
Christopher Graber @idsensei.bsky.social · 10/04/2025
was hesitant to spend my free time on a medical drama, but I might have to be in now
010
Christopher Graber @idsensei.bsky.social · 03/04/2025
bring it, rheumatology
021
Christopher Graber @idsensei.bsky.social · 03/04/2025
c’mon, like we in ID don’t have enough on our plate already
110
Reposted by Christopher Graber
ᐯIᑕTOᖇ ᑎIᘔET, ᗰᗪ @nizet.bsky.social · 01/04/2025
The International Committee on Systematics of Prokaryotes (ICSP) reclassifies Group B 𝘚𝘵𝘳𝘦𝘱𝘵𝘰𝘤𝘰𝘤𝘤𝘶𝘴 as its own genus: 𝘎𝘢𝘭𝘢𝘤𝘵𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘭𝘢𝘯𝘤𝘦𝘧𝘪𝘦𝘭𝘥𝘪𝘪 I knew this was possible (e.g. 𝘌𝘯𝘵𝘦𝘳𝘰𝘤𝘰𝘤𝘤𝘶𝘴 used to be Group D 𝘚𝘵𝘳𝘦𝘱𝘵𝘰𝘤𝘰𝘤𝘤𝘶𝘴) but still caught me by surprise Cool they are honoring Rebecca Lancefield!
news.rr.nihalnavath.com
ICSP Defines New Firmicutes Genus: 𝘎𝘢𝘭𝘢𝘤𝘵𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘭𝘢𝘯𝘤𝘦𝘧𝘪𝘦𝘭𝘥𝘪𝘪
The International Committee on Systematics of Prokaryotes Renames Group B 𝘚𝘵𝘳𝘦𝘱𝘵𝘰𝘤𝘰𝘤𝘤𝘶𝘴 as 𝘎𝘢𝘭𝘢𝘤𝘵𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘭𝘢𝘯𝘤𝘦𝘧𝘪𝘦𝘭𝘥𝘪𝘪
1207
Reposted by Christopher Graber
Paul Adamson MD MPH @padamsonmd.bsky.social · 17/02/2025
Drug-resistant #gonorrhea is an urgent issue, threatening our empiric treatment options. Resistance to ceftriaxone is rapidly increasing in the Asia-Pacific region. Happy to share our study from Vietnam, now out in @jidjournal.bsky.social academic.oup.com/jid/article/... #IDsky #STIsky #AMR
academic.oup.com
High prevalence of ceftriaxone-resistant Neisseria gonorrhoeae in Hanoi, Vietnam, 2023-2024
This study, from Hanoi, Vietnam between 2023-2024, observed a 27% prevalence of ceftriaxone resistance among 352 Neisseria gonorrhoeae isolates. Whole-geno
12711
Reposted by Christopher Graber
UCLA Department of Medicine @domucla.bsky.social · 04/03/2025
Groundbreaking research from Dr. Joanna Schaenman! Her findings reveal how COVID-19 impacts organ transplant patients differently than others and highlight the urgent need for tailored treatment approaches for this vulnerable population. Read more: uclahs.fyi/41gGK6d
021
Christopher Graber @idsensei.bsky.social · 04/03/2025
things we will discuss at the upcoming UCLA ID fellowship ORTBO
120
Reposted by Christopher Graber
Paul Adamson MD MPH @padamsonmd.bsky.social · 26/02/2025
#Measles case reported in Los Angeles County LAX is a big airport and this is a long time frame = many people w/ potential exposure A good plug for #vaccines, because you never know when you might be exposed. publichealth.lacounty.gov/phcommon/pub...
BACKGROUND INFORMATION • The identified case is a non-Los Angeles County resident who traveled to LAX on February 19, 2025. • The person arrived on: Korean Air Flight KAL11/KE11 Tom Bradley International Terminal B • Individuals who were at Terminal B from approximately 1:00 p.m. to 4:00 p.m. may be at risk of developing measles from 7 to 21 days from the exposure date. Exposed individuals who have been free of symptoms for more than 21 days (March 11th) are no longer at risk.PEOPLE WHO WERE AT THE EXPOSURE LOCATION ON THE DATE AND TIME MENTIONED SHOULD • Review their immunization records to determine if they are protected against measles. • Those who have not had measles in the past and have not yet received a measles vaccine are at risk of developing measles after being exposed. Notify their health care provider as soon as possible about potential exposure if they are pregnant, an infant, have a weakened immune system and/or are unimmunized Monitor for illness with fever and unexplained rash from 7 days to 21 days after exposure. If symptoms develop, stay home, avoid school, work or any large gathering and call a healthcare provider immediately • Call any healthcare facility before entering and let them know about their measles exposure and symptoms
084
Christopher Graber @idsensei.bsky.social · 26/02/2025
Connect the organisms with an antibiotic that covers all four in each group! connections.swellgarfo.com/game/-OK2cZ4...
connections.swellgarfo.com
Connections – Bugs and Drugs
Create custom puzzles based on the game popularized by New York Times
120